Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib

Following the initial success of imatinib as frontline therapy for chronic myeloid leukemia (CML), several second-generation therapeutics have been developed with increased potency and the ability to inhibit the majority of imatinib-resistant mutations. Here, we review the current knowledge about the target specificity of the two new inhibitors nilotinib and dasatinib in comparison to imatinib, including the recent large-scale chemical proteomics screens.


Published in:
Leukemia & lymphoma, 49, 4, 615-9
Year:
2008
ISSN:
1029-2403
Laboratories:




 Record created 2011-03-21, last modified 2018-09-13


Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)